The development of allogeneic Vδ1 T cells expressing a glypican-3 (GPC-3)-targeted chimeric antigen receptor (CAR) [73] and secreting IL-15 is explored as a potential cell therapy for HCC and other GPC-3-expressing tumors [74]. The gene discussed is GPC3; the disease is hepatocellular carcinoma.